Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2004
Reporting Period: Event-based report regarding regulatory approval.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is regulatory in nature. The U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health, approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the Company's OraQuick® Rapid HIV-1/2 Antibody Test.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on June 25, 2004, announcing the FDA waiver approval. This information is incorporated by reference as Exhibit 99.1.
Outlook and Risks: The filing does not provide specific financial guidance, future outlook projections, or a discussion of risks and contingencies beyond the regulatory event itself.
Investor Verification Checklist
- Verify the specific terms and limitations of the CLIA waiver approved by the FDA for the OraQuick® Rapid HIV-1/2 Antibody Test.
- Review the full text of the press release attached as Exhibit 99.1 for details on market impact or distribution changes.
- Confirm if this waiver alters the testing requirements for laboratories using the OraQuick test.